Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of N-acetylcysteine for the prevention of carboplatin-induced nephrotoxicity in ovarian, fallopian tube and primary peritoneal cancer patients
TCTR20260310007Phase 2Recruiting
- Sponsor
- Rajavithi Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acetylcysteine in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Rajavithi Hospital. Started Jan 2026; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on TCTR20260310007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260310007.